Item 2.05 Costs Associated with Exit or Disposal Activities.
On
The Company estimates that it will incur aggregate pre-tax charges of
approximately
Item 7.01 Regulation FD Disclosure.
On
The information under this Item 7.01 and the accompanying Exhibit 99.1 shall be deemed "furnished" and not "filed" under Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any filings made by the Company under the Securities Act of 1933, as amended, or the Exchange Act except as may be expressly set forth by specific reference in such filing.
Note Regarding Forward-Looking Statements.
This Current Report on Form 8-K regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements include, but are not limited to, express or implied statements related to the intended benefits of the Company's Restructuring, in; the number of employees impacted by the Restructuring and the timing of completion of the Restructuring; the Company's expected cash runway; and the therapeutic potential of gavo-cel, TC-510 and TCR2's other product candidates, including potential improvements in efficacy, safety and durability in the Phase 2 portion of the gavo-cel trial, expectations regarding future growth and prospects, future clinical development plans and anticipated timing of data updates, the development of the Company's TRuC-T cells, their potential characteristics, applications and clinical utility, the potential therapeutic applications of the Company's TRuC-T cell platform.
Any forward-looking statements are based on management's current expectations of
future events and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. Risks that contribute to the
uncertain nature of the forward-looking statements include, without limitation:
the risk that the Company may not be able to implement the Restructuring as
currently anticipated or within the timing currently anticipated, the impact of
the workforce reduction on the Company's business, the risk that the Company's
cost saving initiatives may not be successful, unanticipated difficulties with
preserving capital, unanticipated difficulties in terminating certain contracts
and arrangements, unanticipated charges not currently contemplated that may
occur as a result of the Restructuring, and uncertainties inherent in clinical
studies. For a discussion of these risks and uncertainties, and other important
factors, any of which could cause the Company's actual results to differ from
those contained in the forward-looking statements, see the section entitled
"Risk Factors" in the Company's most recent Annual Report on Form 10-K, most
recent Quarterly Report on Form 10-Q and its other filings with the
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description 99.1 Press release datedJanuary 5, 2023 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source